SINOFUTURE PHARMA specialises in the production of steroidal, niche non-steroidal APIs. Our expertise extends to custom manufacturing solutions tailored to meet the specific needs of our clients. Presently, we operate 2 R&D centers and 2 manufacturing sites. Both sites have successfully passed inspections and audits for advanced intermediates and APIs by leading global pharmaceutical companies, including Novartis, MSN, BDR, Lupin,as well as major European partners such as Sanofi, Roche.

Sourcing of API、Intermediates and KSM for regulated market.This is our integrated business. Our founding team has over a decade of industry experience, with successful market expansion in Japan, India, Korea, and Europe, earning a strong reputation and extensive international expertise. Currently we have channelized our platform of stable business with the world's top 50 pharmaceutical companies, and have long-term cooperation with the TOP 200 Indian pharmaceutical companies, we’re still working on continuing to strengthen our relationship.

We collaborate with our strategic partner for APIs & Nutritional Supplements import Registration and marketing activity.We can provide suppliers with a simple, and hassle free process through which they can do the registration in China. We adhere to strict confidentiality norms, and look to make the process quick, and smooth for the producer.

Working closely with partner manufacturers, providing professional consultation for DMF registration and EU-GMP compliance, including DMF compilation, submission, and deficiency response, gap analysis, pre-inspection, improvement strategies, during the whole drug lifecycle, including annual report and post-approval change, to ensure drug registration approval and GMP compliance in the international markets, e.g. US, Europe, Asia, Africa, etc.